American Biogen Inc. is a global leader in biotechnology, engaged in scientific research and development of a wide range of medications for treatment of people with hematological, neuralgic and autoimmune diseases. As of today, Biogen is the third largest biotech company in the world. Company's financial gain as of 2015 equaled almost $ 3 billion. Scientific centers and hubs of Biogen Inc. are allocated in over 30 countries, where about 8,000 employees are engaged in various activities. One of the latest projects is Alprolix. It gained a worldwide recognition no more than a year after its first release in 2014 and was highly appraised by Medical Reviewers. Alprolix prevents most fatal bleedings and acts as a prophylactic agent for people with hemophilia.
Nyní budete vždy vědět, do kterých akcií je výhodnější investovat